Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses

• Published in: British journal of haematology Vol. 195; no. 2; pp. 201 - 209
• Main Authors: Landsburg, Daniel J., Barta, Stefan K., Ramchandren, Radhakrishnan, Batlevi, Connie, Iyer, Swaminathan, Kelly, Kevin, Micallef, Ivana N., Smith, Sonali M., Stevens, Don A., Alvarez, Mariano, Califano, Andrea, Shen, Yao, Bosker, Gideon, Parker, Jefferson, Soikes, Raul, Martinez, Elizabeth, Roemeling, Reinhard, Martell, Robert E., Oki, Yasuhiro
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.10.2021
• Subjects: B-cell lymphoma; biomarker; Biomarkers; Biomarkers, Tumor - analysis; Clinical trials; Copy number; diffuse large B‐cell lymphoma; Female; Gene rearrangement; Hematology; Histone deacetylase; histone deacetylase inhibitor; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - therapeutic use; Humans; Kinases; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - genetics; Male; Middle Aged; Morpholines - administration & dosage; Morpholines - therapeutic use; MYC; Myc protein; Patients; phosphatidylinositol 3‐kinase inhibitor; Phosphoinositide-3 Kinase Inhibitors - administration & dosage; Phosphoinositide-3 Kinase Inhibitors - therapeutic use; Predictive Value of Tests; Proteins; Proto-Oncogene Proteins c-myc - genetics; Pyrimidines - administration & dosage; Pyrimidines - therapeutic use; Recurrence; Safety; Treatment Outcome; phosphatidylinositol 3-kinase inhibitor; diffuse large B-cell lymphoma; biomarker; MYC; histone deacetylase inhibitor

Summary Fimepinostat (CUDC‐907), a first‐in‐class oral small‐molecule inhibitor of histone deacetylase and phosphatidylinositol 3‐kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high‐grade B‐cell lymphomas (DLBCL/HGBL), particularly those...